Company news
Skrr Exploration, Inc. (TSXV:SKRR) news
Skrr Exploration, Inc. news releases on 6ix. Latest, Aug 2, 2007: Biomira announces second quarter 2007 financial results
Press releases — page 4
Biomira announces second quarter 2007 financial results
August 2, 2007
Biomira appoints industry veteran as Chief Operating Officer
July 17, 2007
Biomira files investigational new drug application for PX-478, a novel inhibitor of hypoxia-inducible factor-1 alpha
July 3, 2007
Biomira to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
May 8, 2007
Biomira Inc. announces first quarter 2007 results
April 26, 2007
Biomira selects PX-866 as clinical development candidate and presents promising preclinical data at AACR
April 16, 2007
Biomira reports Full year and Fourth Quarter 2006 Financial Results
March 8, 2007
Biomira to present at two upcoming investor conferences
March 7, 2007
Biomira restates U.S. GAAP note disclosure for non-cash charges
March 2, 2007
Biomira announces March 8th webcast of its fourth quarter and full year 2006 financial results conference call
March 2, 2007
First patient enrolled in Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer
February 26, 2007
Biomira to present at the BIO CEO & Investor Conference 2007
February 8, 2007
Eric Baker retires from Biomira's Board of Directors
January 22, 2007
Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer now open for patient enrollment
January 2, 2007
Phase II clinical trial of Biomira's PX-12 in patients with advanced pancreatic cancer now open for patient enrollment
January 2, 2007
Biomira announces U.S. $13 million financing
December 13, 2006
Biomira receives special protocol assessment from the FDA for Phase III trial of Stimuvax for non-small cell lung cancer
December 12, 2006
Biomira Inc. announces third quarter 2006 results
November 2, 2006
Biomira Announces Acquisition of ProlX Pharmaceuticals
October 31, 2006
Biomira Inc. Announces U.S. $100 Million Shelf Registration
September 27, 2006
Biomira Appoints Robert Kirkman President and CEO
August 30, 2006
Biomira Inc. Announces Second Quarter 2006 Results
July 27, 2006
Biomira Stimuvax(R) (L-BLP25) Prostate Cancer Study Results Published
July 20, 2006
Biomira Retains Janney Montgomery Scott to Explore Pipeline Development Options
June 20, 2006
Dr. Alex McPherson Steps Down from Biomira's Board of Directors
June 1, 2006
Biomira Board appoints Edward A. Taylor to Board of Directors
May 18, 2006
Biomira to web cast 2006 Annual General Meeting
May 16, 2006
Phase 2a results in ovarian cancer reported by Biomira's commercialization partner Prima BioMed
May 16, 2006
Biomira Inc. - Annual General Meeting Webcast - May 17, 2006
May 15, 2006
Biomira announces final Phase 2b survival results of Stimuvax(R) (formerly known as BLP25 Liposome Vaccine) trial in patients with non-small cell lung cancer
April 28, 2006
Biomira Inc. announces first quarter 2006 results
April 27, 2006
Dr. Alex McPherson Steps Down as President and CEO of Biomira
April 3, 2006
Biomira Inc. announces year-end results
March 9, 2006
Biomira completes U.S. $16.07 million financing
February 8, 2006
Biomira President & CEO to Participate in Cancer Immunotherapy Focus Session at BIO CEO & Investor Conference
February 8, 2006
Biomira announces U.S. $16.1 million financing
January 27, 2006
Conference call replay information - Biomira Inc.
January 26, 2006
Biomira Inc. announces amendment to licensing agreement for BLP25 Liposome Vaccine
January 26, 2006
BLP25 Liposome Vaccine phase 2 study interim results indicate no safety concerns with reformulated vaccine
November 17, 2005
Biomira to present at Bio-Europe 2005
November 7, 2005
Biomira Inc. announces results for the period ended September 30, 2005
October 27, 2005
Biomira announces BLP25 Liposome Vaccine Phase 2B data published in Journal of Clinical Oncology
September 23, 2005
Biomira announces change to timetable for BLP25 Liposome Vaccine phase 3 trial
September 23, 2005
Biomira announces completion of enrolment in BLP25 Liposome Vaccine phase 2 safety study
September 13, 2005
Biomira announces PRA International to assist with completion of BLP25 Liposome Vaccine Phase 3 study in non-small cell lung cancer
September 12, 2005
Biomira to present at Bear Stearns 18th Annual Healthcare Conference
September 8, 2005
Biomira Inc. announces 2nd quarter results
July 27, 2005
Biomira retains Financial Dynamics as communications advisor
July 26, 2005
Biomira exercises rights in Prima BioMed Ltd.
July 19, 2005
Biomira to present at 8th International Workshop on Carcinoma-Associated Mucins Conference
July 7, 2005